D1 and D5 Receptors
D1 and D5 receptors (also known as D1-like receptors) are a subset of the dopamine receptor G-protein-coupled receptor family that also includes D2, D3 and D4. The two receptor subtypes are highly homologous and very few ligands are selective between them.
D1 and D5 Receptor Agonists |
|
|---|---|
| Cat. No. | 产品名称/活性 |
| 1534 | A 68930 hydrochloride |
| Potent and selective D1-like agonist | |
| 1701 | A 77636 hydrochloride |
| Potent and selective D1-like agonist; orally active | |
| 2073 | (R)-(-)-Apomorphine hydrochloride |
| Dopamine agonist; non-subtype-selective | |
| 1249 | CY 208-243 |
| Selective D1-like agonist | |
| 0884 | Dihydrexidine hydrochloride |
| Selective D1-like agonist | |
| 3548 | Dopamine hydrochloride |
| Endogenous agonist at dopamine D1-5 receptors | |
| 1659 | Fenoldopam hydrochloride |
| Selective D1-like partial agonist | |
| 0922 | SKF 38393 hydrobromide |
| Selective D1-like agonist | |
| 1447 | SKF 81297 hydrobromide |
| D1 agonist | |
| 2075 | SKF 83822 hydrobromide |
| Selective D1-like agonist | |
D1 and D5 Receptor Antagonists |
|
| Cat. No. | 产品名称/活性 |
| 1674 | LE 300 |
| Potent and selective D1 antagonist | |
| 0925 | SCH 23390 hydrochloride |
| Selective D1-like antagonist; also 5-HT2C agonist and Kir3 channel blocker | |
| 2299 | SCH 39166 hydrobromide |
| High affinity D1-like antagonist | |
| 1586 | SKF 83566 hydrobromide |
| Potent and selective D1-like antagonist; also inhibits adenylyl cyclase 2 | |
D1 and D5 receptors (also known as D1-like receptors) are a subset of the dopamine receptor G-protein-coupled receptor family that also includes D2, D3 and D4. The two receptor subtypes are highly homologous and very few ligands have been identified that are selective between the D1 and D5 subtypes. D1 receptors are widely expressed throughout the brain, whereas D5 receptors show a restricted distribution (mainly limbic areas).
External sources of pharmacological information for D1 and D5 Receptors :
Literature for D1 and D5 Receptors
Tocris offers the following scientific literature for D1 and D5 Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Our Dopamine receptors review gives an overview of the dopamine receptor subtypes, and the receptor agonists and antagonists used to study them.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF